GSK plc (NYSE:GSK) Shares Bought by Stockman Wealth Management Inc.

Stockman Wealth Management Inc. lifted its holdings in GSK plc (NYSE:GSK) by 3.7% during the 4th quarter, HoldingsChannel.com reports. The firm owned 217,200 shares of the pharmaceutical company’s stock after acquiring an additional 7,683 shares during the quarter. Stockman Wealth Management Inc.’s holdings in GSK were worth $7,346,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Eastern Bank acquired a new position in shares of GSK in the third quarter worth about $26,000. Crews Bank & Trust acquired a new stake in shares of GSK during the fourth quarter worth approximately $26,000. ST Germain D J Co. Inc. boosted its holdings in shares of GSK by 195.5% during the fourth quarter. ST Germain D J Co. Inc. now owns 789 shares of the pharmaceutical company’s stock worth $27,000 after purchasing an additional 522 shares during the period. Sunbelt Securities Inc. boosted its holdings in shares of GSK by 73.8% during the third quarter. Sunbelt Securities Inc. now owns 711 shares of the pharmaceutical company’s stock worth $29,000 after purchasing an additional 302 shares during the period. Finally, Concord Wealth Partners boosted its holdings in shares of GSK by 231.8% during the third quarter. Concord Wealth Partners now owns 783 shares of the pharmaceutical company’s stock worth $32,000 after purchasing an additional 547 shares during the period. 15.74% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several analysts recently commented on the stock. Jefferies Financial Group cut shares of GSK from a “buy” rating to a “hold” rating and decreased their price target for the stock from $53.00 to $39.50 in a report on Tuesday, November 12th. Guggenheim cut shares of GSK from a “buy” rating to a “neutral” rating in a report on Thursday, October 31st. StockNews.com upgraded shares of GSK from a “buy” rating to a “strong-buy” rating in a research note on Friday. Finally, Deutsche Bank Aktiengesellschaft cut shares of GSK from a “buy” rating to a “hold” rating in a research note on Friday, November 15th. Six investment analysts have rated the stock with a hold rating and four have issued a strong buy rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $43.25.

GSK Trading Down 1.0 %

NYSE:GSK opened at $36.03 on Friday. GSK plc has a 12 month low of $31.72 and a 12 month high of $45.92. The firm has a market cap of $74.68 billion, a price-to-earnings ratio of 22.66, a P/E/G ratio of 1.42 and a beta of 0.64. The company has a quick ratio of 0.53, a current ratio of 0.78 and a debt-to-equity ratio of 1.12. The company’s 50 day moving average is $34.25 and its 200-day moving average is $37.57.

GSK (NYSE:GSK) last announced its earnings results on Wednesday, February 5th. The pharmaceutical company reported $0.59 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.44 by $0.15. GSK had a net margin of 8.13% and a return on equity of 48.59%. Equities analysts anticipate that GSK plc will post 4.07 EPS for the current year.

GSK Increases Dividend

The business also recently announced a quarterly dividend, which will be paid on Thursday, April 10th. Investors of record on Friday, February 21st will be given a dividend of $0.3932 per share. The ex-dividend date of this dividend is Friday, February 21st. This represents a $1.57 dividend on an annualized basis and a yield of 4.36%. This is a positive change from GSK’s previous quarterly dividend of $0.39. GSK’s payout ratio is 93.08%.

GSK Company Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.